FIELD: pharmaceuticals.
SUBSTANCE: group of inventions relates to treatment of cancer. The pharmaceutical composition for treating cancer includes 150 mg/ml anti-PD-1 antibody; 20 mM histidine buffer; 84 mg/ml trehalose; 0.2 mg/ml PS80 and 0.045 or 0.05 mg/ml EDTA, wherein said pharmaceutical composition has a pH of 5.0 +/- 0.5 . Also disclosed is another variant of implementation of the pharmaceutical composition.
EFFECT: composition with a high concentration of the antibody and reduced viscosity.
28 cl, 7 dwg, 26 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | 2018 |
|
RU2766590C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODIES DIRECTED TO PROTEIN OF PROGRAMMED DEATH OF CELL-1 (PD-1) | 2014 |
|
RU2723050C2 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| ANTI-TIGIT ANTIBODIES AND METHODS OF USING | 2016 |
|
RU2732591C2 |
| ANTI-LAG-3 DOSING REGIMENS AND THEIR USE | 2018 |
|
RU2801208C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
